Published in Gynecol Oncol on December 23, 2008
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
Role of progesterone in endometrial cancer. Semin Reprod Med (2010) 1.53
Estrogen receptors and human disease: an update. Arch Toxicol (2012) 1.22
Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol (2015) 0.98
microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep (2011) 0.95
Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch (2014) 0.90
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2013) 0.90
High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: implications for racial disparity of prostate cancer. Carcinogenesis (2013) 0.88
Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J Surg Oncol (2015) 0.87
Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis. Horm Cancer (2011) 0.86
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). BMC Cancer (2014) 0.85
Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET. Eur J Nucl Med Mol Imaging (2010) 0.84
Controversies in the management of endometrial carcinoma. Obstet Gynecol Int (2010) 0.84
Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. Diagn Pathol (2014) 0.84
Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. BMC Cancer (2012) 0.83
Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERα. PLoS One (2014) 0.82
The estrogen receptor joins other cancer biomarkers as a predictor of outcome. Obstet Gynecol Int (2013) 0.81
Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate. Oncol Lett (2012) 0.81
Does Metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer? Diabetol Metab Syndr (2013) 0.80
Hypermethylation of SOX2 Promoter in Endometrial Carcinogenesis. Obstet Gynecol Int (2010) 0.79
Progesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma. Ecancermedicalscience (2013) 0.79
Eight functional polymorphisms in the estrogen receptor 1 gene and endometrial cancer risk: a meta-analysis. PLoS One (2013) 0.77
Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecol Oncol (2016) 0.77
Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors. PLoS One (2015) 0.76
Leptin receptor expression during the progression of endometrial carcinoma is correlated with estrogen and progesterone receptors. Arch Med Sci (2016) 0.75
RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. Eur J Cancer (2016) 0.75
Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition. Int J Gynecol Cancer (2017) 0.75
Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival. Br J Cancer (2016) 0.75
Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep (2016) 0.75
Nucleophosmin/B23 is a negative regulator of estrogen receptor α expression via AP2γ in endometrial cancer cells. Oncotarget (2016) 0.75
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res (2010) 2.03
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol (2005) 2.01
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol (2010) 1.84
In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med (2007) 1.79
Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer (2009) 1.70
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med (2011) 1.62
Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol (2009) 1.53
Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.43
A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A (2002) 1.41
Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol (2003) 1.36
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res (2010) 1.27
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol (2005) 1.24
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med (2010) 1.23
Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer (2006) 1.23
Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol (2003) 1.17
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. Proc Natl Acad Sci U S A (2011) 1.17
An oncological view on the blood-testis barrier. Lancet Oncol (2002) 1.15
Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res (2011) 1.13
Vulvar carcinoma. The price of less radical surgery. Cancer (2002) 1.12
Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol (2006) 1.08
PMS2 involvement in patients suspected of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.07
Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer (2012) 1.07
Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat (2012) 1.06
Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res (2009) 1.03
Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol (2011) 1.01
The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol (2009) 1.00
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res (2009) 0.99
Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. Epigenetics (2012) 0.98
Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther (2004) 0.97
Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev (2005) 0.97
The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer (2010) 0.95
TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol (2006) 0.95
Gene promoter methylation patterns throughout the process of cervical carcinogenesis. Cell Oncol (2010) 0.95
Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Eur J Cancer (2005) 0.95
Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res (2012) 0.94
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int J Cancer (2012) 0.94
Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol (2005) 0.93
Hyperplastic polyps in hereditary nonpolyposis colorectal cancer. Am J Gastroenterol (2003) 0.92
Mononucleotide precedes dinucleotide repeat instability during colorectal tumour development in Lynch syndrome patients. J Pathol (2009) 0.92
RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res (2005) 0.92
Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther (2004) 0.91
Bronchoalveolar lavage fluid characteristics in acute and chronic lung transplant rejection. J Heart Lung Transplant (2004) 0.91
VEGF-SPECT with ¹¹¹In-bevacizumab in stage III/IV melanoma patients. Eur J Cancer (2011) 0.88
P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy. Int J Cancer (2007) 0.88
Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. Clin Chem (2003) 0.88
Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res (2005) 0.87
Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression. J Immunother (2011) 0.87
Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. BMC Pulm Med (2014) 0.87
A critical appraisal of circumferential resection margins in esophageal carcinoma. Ann Surg Oncol (2010) 0.86
The prognostic value of TRAIL and its death receptors in cervical cancer. Int J Radiat Oncol Biol Phys (2009) 0.86
Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat (2007) 0.86
Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol (2010) 0.85
Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer. Int J Gynecol Cancer (2011) 0.85
Multiple VEGF family members are simultaneously expressed in ovarian cancer: a proposed model for bevacizumab resistance. Curr Pharm Des (2012) 0.85
Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus. Neoplasia (2004) 0.85
Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys (2006) 0.84
No association between two MLH3 variants (S845G and P844L)and colorectal cancer risk. Cancer Genet Cytogenet (2004) 0.84
Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia. Int J Cancer (2006) 0.84
Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL. J Pathol (2013) 0.83
The role of ATM and 53BP1 as predictive markers in cervical cancer. Int J Cancer (2012) 0.83
Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res (2004) 0.83
Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. Genes Chromosomes Cancer (2010) 0.83
The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer. Hum Pathol (2010) 0.83
Early carcinogenic events in HNPCC adenomas: differences with sporadic adenomas. Dig Dis Sci (2008) 0.83
Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecol Oncol (2009) 0.83
Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas. Int J Cancer (2012) 0.82
Telomerase in relation to expression of p53, c-Myc and estrogen receptor in ovarian tumours. Int J Oncol (2003) 0.82
Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers. Radiother Oncol (2013) 0.82
Do microsatellite instability profiles really differ between colorectal and endometrial tumors? Genes Chromosomes Cancer (2009) 0.82
Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer (2009) 0.82
Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. Gynecol Oncol (2012) 0.80
Effect of tamoxifen on the endometrium and the menstrual cycle of premenopausal breast cancer patients. Int J Gynecol Cancer (2009) 0.80
Sulindac treatment in hereditary non-polyposis colorectal cancer. Eur J Cancer (2007) 0.80
High frequency of RPL22 mutations in microsatellite-unstable colorectal and endometrial tumors. Hum Mutat (2014) 0.80
Radical surgery in patients with residual disease after (chemo)radiation for cervical cancer. Int J Gynecol Cancer (2014) 0.79
Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors. Int J Oncol (2005) 0.79
A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. Int J Cancer (2008) 0.79
A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease. Antivir Ther (2006) 0.79
New target genes in endometrial tumors show a role for the estrogen-receptor pathway in microsatellite-unstable cancers. Hum Mutat (2014) 0.78
Model of care for women at increased risk of breast and ovarian cancer. Maturitas (2011) 0.78
Value of RT-PCR analysis of sentinel nodes in determining the pathological nodal status in colon cancer. Anticancer Res (2007) 0.78
Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification. Histopathology (2013) 0.77
A substantial proportion of microsatellite-unstable colon tumors carry TP53 mutations while not showing chromosomal instability. Genes Chromosomes Cancer (2005) 0.77
Vulvar melanoma: is there a role for sentinel lymph node biopsy? Cancer (2002) 0.77
Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma. Cancer Lett (2004) 0.77
TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. J Pathol (2010) 0.76